Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GILD

3 Stocks to Help You Make Passive Income in 2022

Concerns over the Fed’s aggressive interest rate hikes and growing odds of the economy sliding into a recession are expected to keep the stock market highly volatile in the upcoming months. Amid these volatile market conditions, it could be wise to invest in high dividend-yielding stocks Texas Instruments (TXN), Visa…

StockNews.com

2 Oversold Stocks Investors Will Want to Buy Before They Blast Off

The stock market sell-offs triggered by macroeconomic and geopolitical issues since the beginning of the year have driven many quality stocks into the oversold territory. So, it could be wise to invest in oversold stocks Gilead Sciences (GILD) and Comcast (CMCSA), which have solid rebound potential. Let’s discuss….

StockNews.com

Gilead Sciences Whale Trades For July 14

Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions

Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture away from the HIV franchise.

Benzinga

2 Bargain Healthcare Stocks Yielding 4%

Despite the market volatility, the healthcare sector is outperforming. Thus, we think it could be wise to buy dividend-paying healthcare stocks Gilead Sciences (GILD) and Dow (DOW), which look undervalued at their current price levels. These bargain stocks are rated Buy in our proprietary rating system.

StockNews.com

Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market capitalization of $74.42 billion.

Benzinga

3 Low-Beta Stocks to Buy to Combat a Jittery Market

The Fed’s aggressive interest rate increases to tame multi-decade high inflation, and an anticipated economic slowdown, have exacerbated market volatility of late. To protect against the market uncertainties, we think investors should consider investing in low-beta stocks Merck (MRK), Gilead Sciences (GILD), and AmerisourceBergen (ABC). Let’s discuss why.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

StockNews.com

Why These Analysts Are Bullish On Gilead's Q1 Earnings

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses. The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table. HIV sales,…

Benzinga

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.56% on an annualized basis producing an average annual return of 14.71%. Currently, Gilead Sciences has a market capitalization of $75.20 billion.

Benzinga

Where Gilead Sciences Stands With Analysts

Over the past 3 months, 11 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus

Gilead Sciences, Inc. (NASDAQ: GILD) reported firs

Benzinga

Gilead Sciences Crushes First-Quarter Views As Covid Drug Adds $1.5 Billion

Gilead beat first-quarter estimates on Thursday, though offered a profit view that was a penny light at the midpoint, and GILD stock fell.

Investors Business Daily

Recap: Gilead Sciences Q1 Earnings

Gilead Sciences (NASDAQ:GILD) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Gilead Sciences's Earnings Outlook

Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Gilead Sciences will report an earnings per share (EPS) of $1.80.

Benzinga

Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients

The FDA has approved Gilead Sciences Inc's (NASDAQ:GILD) supplemental marketing application for Veklury (remdesivir) for pediatric COVID-19 patients older than 28 days. The approval covers patients weighing at least 3 kg and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe infection. This approval…

StockNews.com

Looking for Value Stocks to Add to Your Portfolio? Here are 5 For Your List

Heightened inflationary pressure, deepening supply chain disruptions, and the possibility of aggressive interest rate hikes later this year have fostered a volatile stock market. Because these factors are not expected to abate anytime soon, we think investors looking to generate solid long-term returns could consider betting on the stocks of…

Benzinga

If You Invested $1000 In Gilead Sciences 20 Years Ago, Here's How Much You Would Have Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.99% on an annualized basis producing an average annual return of 15.38%. Currently, Gilead Sciences has a market capitalization of $79.98 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Where Gilead Sciences Stands With Analysts

Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings:

Benzinga

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 13.94%. Currently, Gilead Sciences has a market capitalization of $75.77 billion.

Benzinga

10 Biggest Price Target Changes For Monday

Wells Fargo cut the price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $70 to $63. Gilead Sciences shares rose 0.4% to $59.91 in pre-market trading.

StockNews.com

4 Best High-Yield Stocks on the S&P 500: Phillips 66, Gilead, Valero, and Walgreen Boots

The stock market has been experiencing high volatility due to surging inflation, the Ukraine-Russia war, and multiple interest rate increases planned by the Fed this year. So, investors looking to side-step the market’s volatility could be well served by betting on high dividend-yielding stocks. Gilead Sciences (GILD), Walgreens Boots Alliance…

Benzinga

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.58% on an annualized basis.

StockNews.com

Trading Near 52-Week Lows: Grab These 5 Undervalued Healthcare Stocks Now

Despite possessing solid long-term growth prospects on the back of rising demand from an aging population, many healthcare stocks have been hard hit by the broader market sell-offs over the past couple of months. But given the near-inelastic demand for healthcare solutions and the industry’s long-term growth prospects, we think…

Benzinga

Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint

Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer.

1 … 5 6 7 8

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.